🔗 Share this article

Given that the United States undertakes unprecedented adjustments to its vaccine schedules, an unexpected name appears unexpectedly: Høeg, a Danish American sports medicine doctor and public health researcher who initially gained attention by expressing skepticism about coronavirus shots in the global health crisis and has concentrated on alleged fatalities following Covid vaccination in her brief tenure at the US Food and Drug Administration (FDA).

Planned Overhauls to Childhood Vaccine Schedule

Public health authorities had intended to unveil radical changes to the pediatric vaccination calendar recently, bringing the US with Denmark’s vaccine program, according to reports – a major change that would place the US out of step with many the international standard with insufficient data for benefit. This reveal has been delayed until the new year.

Instead of the director of the vaccine center, Høeg is scheduled to address the audience at the meeting. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth person to lead the division this year.

A New Direction at the Agency

The acting appointment could signify a tighter collaboration between the pharmaceutical and vaccine divisions as Høeg and Prasad consolidate power at the regulatory agency – and it suggests a increased emphasis upon dismantling long-standing immunizations at the FDA.

Dr. Høeg has frequently advocated for halting certain pediatric vaccine recommendations in the US so as to align more in line with Denmark, a country with universal health coverage and a population roughly the size of the state of Wisconsin.

In her initial public appearances, she has kept her attention on immunizations – traditionally the responsibility of Dr. Prasad, chief of the FDA’s CBER – rather than pharmaceutical oversight.

Concerns Over Expertise

Dr. Høeg has no apparent background in drug development, oversight or administrative roles, which has been typical for previous heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the commissioner and the vaccine center since March.

“She appears not to have the requisite experience” for leading the CDER, stated Jonathan Howard. “She lacks experience running a scientific study. She is not versed in managing a large organization. She is not an expert in industry regulation.”

Former heads of the center would “grasp legal statutes and the science of medication creation”, noted Janet Woodcock. “Objectively, she doesn’t have the type of experience that previous people who led CBER have had.”

CDER has an immense portfolio at the agency, the former commissioner stated.

“Everybody just pays attention on the innovative therapies, but the off-patent medication office authorizes thousands of generic drugs. There’s a biologic copycat branch, OTC medication office and more, and all of those have to be managed,” she noted. “The area you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a substantial leadership aspect to the position, which manages in excess of 5,000 employees. “It is a huge administrative position, if you perform it correctly,” the former official added.

Agency Reaction and Controversial Initiatives

When asked about questions about Høeg’s qualifications and whether this assignment represents greater collaboration among agency officials on vaccines, a press secretary responded that the “inquiries stem from incorrect assumptions”.

“Her experience is consistent with the functions of her job,” the spokesperson stated, citing the period Høeg spent guiding the FDA commissioner on “pharmaceutical safety and oversight research, including computerized risk analysis and immunization monitoring”.

As acting director, Høeg inherits the commissioner’s new priority voucher program, a contentious one-day drug-approval program that allegedly troubled her preceding directors. “By what process are these drugs being picked for this expedited pathway? Who takes the decisions?” Howard said. “There’s a lot of lack of transparency happening at the FDA right now.”

In general, he stated, “the FDA appears to be shifting towards more relaxed oversight of most medications, with the exception of vaccines.”

Documented History on Immunizations

Concerning immunizations, Høeg has a more established, if troubling, past, Howard have noted. She released a research paper using non-validated crowd-sourced reports to estimate the frequency of myocarditis after Covid immunization. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have changed statistics to imply Covid vaccinations are riskier than they are.

Among her “wish list” for the incoming government included altering guidelines for novel immunizations and discontinuing “unnecessary” vaccines, she said following the vote on a audio program. At the FDA, Dr. Høeg has reportedly suggested barring adolescent males from getting COVID-19 vaccines.

“She is an thorough dogmatist who commences with her conclusions and works backwards to retrofit the data in a extremely misleading, untruthful way,” Dr. Howard said.

Taking Control and a “Revenge Tour”

Høeg became part of fellow contrarians, {like|